Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Pegylated Interferon-Alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75				Other				ML17840 NCT00204529

Last Modified: 4/23/2008 First Published: 1/5/2007


2.		Phase I/II Pilot Study of Gefitinib and PEG-Interferon alfa-2a in Patients With Unresectable or Metastatic Squamous Cell Carcinoma of the Skin

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18				NCI, Pharmaceutical / Industry				UCSD-051205 ZENECA-IRUSIRES0488, NCT00423397

Last Modified: 8/2/2007 First Published: 9/23/2005


3.		Phase II Study of Capecitabine and Pegylated Interferon alfa-2a in Patients With Recurrent or Progressive Brain Metastases Secondary to Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				MDA-2004-0727 6810, NCI-6810, NCT00227656


4.		AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 90				Other				2003.317 NCT00146913

Last Modified: 9/14/2006 First Published: 11/4/2005


5.		Phase I Study of PEG-Interferon alfa-2b in Young Patients With Plexiform Neurofibroma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 months to 21 years				NCI				NCI-05-C-0232 NCI-P6670, NCT00253474

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute